Drug Profile
H 103
Alternative Names: H-103; Oncolytic recombinant adenovirus injection - Shanghai Sunway BiotechLatest Information Update: 28 Nov 2018
Price :
$50
*
At a glance
- Originator Shanghai Sunway Biotech
- Class Antineoplastics; Cancer vaccines; DNA vaccines; Gene therapies; Oncolytic viruses
- Mechanism of Action P53 gene modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Nov 2018 No recent reports of development identified for phase-I development in Cancer in China (Intratumoural, Injection)
- 08 Oct 2015 Phase-I clinical trials in Cancer in China (Intratumoural) before October 2015
- 08 Oct 2015 Shanghai Sunway Biotech completes a phase I trial in Cancer in China (Shanghai Sunway Pipeline, October 2015)